Dermatosis perforante por gefitinib / Gefitinib-induced perforating dermatosis
Actas dermo-sifiliogr. (Ed. impr.)
; 97(3): 208-211, abr. 2006. ilus, tab
Article
em Es
| IBECS
| ID: ibc-044827
Biblioteca responsável:
ES1.1
Localização: ES1.1 - BNCS
RESUMEN
El gefitinib (Iressa®) es un nuevo agente antineoplásico que actúa inhibiendo selectivamente la tirosina cinasa del factor de crecimiento epidérmico (EGFR-TK). Ha demostrado actividad frente a varios tumores sólidos. Por su mecanismo de acción, el gefitinib y otros inhibidores de tirosina cinasa se han asociado a múltiples efectos cutáneos dermatológicos, la mayoría de ellos leves y bien tolerados. Se presenta un caso de dermatosis perforante tras tratamiento con gefitinib
ABSTRACT
Gefitinib (Iressa®) is a new antineoplastic agent that acts by selectively inhibiting epidermal growth factor receptor tyrosine kinase (EGFR-TK). It has shown activity against several solid tumors. Because of their action mechanism, gefitinib and other tyrosine kinase inhibitors have been associated with multiple cutaneous effects, most of which are mild and well tolerated. We present a case of perforating dermatosis after treatment with gefitinib
Buscar no Google
Coleções:
06-national
/
ES
Base de dados:
IBECS
Assunto principal:
Hiperceratose Epidermolítica
/
Erupções Acneiformes
/
Toxidermias
/
Dermatoses Faciais
/
Receptores ErbB
/
Antineoplásicos
Limite:
Adult
/
Humans
/
Male
Idioma:
Es
Revista:
Actas dermo-sifiliogr. (Ed. impr.)
Ano de publicação:
2006
Tipo de documento:
Article